The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components.

Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells CONCORD, Calif.--(BUSINESS WIRE ...

The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the U ...

In transfused subjects, by modified intent to treat (mITT pre-specified primary endpoint population) the incidence of AKI was 29.3% (46/157) for INTERCEPT RBC recipients compared to 28.0% (45/161 ...

This device is part of the INTERCEPT Blood System, designed for use with platelets and plasma. The approval allows Cerus to ...

The INTERCEPT Blood System for platelets and plasma is globally available and holds both CE mark and FDA approval. The system for Cryoprecipitation is approved in the U.S. for producing Pathogen ...

(RTTNews) - Cerus Corporation (CERS) announced the FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately. The ...

Cerus Corporation has obtained CE mark approval for its INT200, a light-emitting diode (LED)-based illumination device, for ...

France and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma. CONCORD, Calif., May 28, 2025--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced ...

The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components.

Presentations and abstracts showcase the broad applicability and expected benefits of the INTERCEPT Blood System for platelets, plasma, IFC, and red blood cells CONCORD, Calif., May 29, 2025 ...